Please assess the completion status of the following clinical trial:

Trial Title: Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic stoke within 72 after onset, confirmed by MRI or CT.~* Age 35-75 years, inclusive.~* Patients with the first attack or patients with stroke history(modified Rankin Scale score 0-1).~* Clear signs of localization of nervous system, NIHSS score 4 to 22.~* Patient or proxy has signed informed consent.~Exclusion Criteria:~* Hemorrhage diseases according to head CT or MRI, such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, haemorrhage after cerebral infarction.~* Transient Ischemic Attack (TIA).~* Severe disturbance of consciousness: 1a of NIHSS score\>1 point; Difficulty in swallowing, unable to take oral capsules; any of 5a, 5b, 6a, 6b of NIHSS score\>2 point.~* Convinced of stroke caused by brain tumor, brain trauma, hemopathy, etc.~* Hemorrhagic tendency patients.~* Patients with endovascular treatment after the onset of stroke.~* Patients with dementia, severe Parkinson's disease, mental disorders, limb dysfunction caused by other diseases or other conditions that may affect the therapeutic efficacy.~* Uncontrolled hypertension (≥200 mmHg systolic or ≥110 mmHg diastolic) or hypotension (≤90 mmHg systolic or ≤60mmHg diastolic); severe hyperglycemia(blood glucose ≥400 mg/dl) or hypoglycemia( blood glucose≤50 mg/dl).~* Severe hepatic insufficiency defined as transaminase values \> 2x upper limit of normal; severe renal insufficiency defined as values serum creatinine\> 1.5x upper limit of normal; cardiac dysfunction or other serious systemic disease with life expectancy ≤3 months.~* Patients with concurrent malignancy or ongoing anti-tumor therapy.~* Patients with history of being allergic to the trial medicine.~* Pregnancy, breastfeeding or potential pregnancy.~* Within three months or currently participating in another investigational study.~* Any other condition that in the opinion of the investigator should preclude study participation.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tongxinluo capsule (Type: EXPERIMENTAL): Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
- placebo capsule (Type: PLACEBO_COMPARATOR): placebo capsule,4 granules,t.i.d. po,for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).